WFA
CPRX

Wipfli Financial Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Wipfli Financial Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$22K Buy
+1,677
New +$19.9K ﹤0.01% 1528

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wipfli Financial Advisors's CPRX Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Catalyst Pharmaceutical (CPRX) in Q3 2022: 1,677 shares worth $22K. The stake represents ﹤0.01% of the portfolio and ranks #1528 among its holdings.

229 funds tracked by Wall St. Rank hold CPRX as of Q3 2022.

  • Wipfli Financial Advisors held 1,677 shares of Catalyst Pharmaceutical worth $22K as of Q3 2022.
  • Catalyst Pharmaceutical was a new Wipfli Financial Advisors position in Q3 2022.
  • Catalyst Pharmaceutical made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1528 holding.
  • 229 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.